4basebio annual return on equity
2023
2024
2025
4basebio Return on Equity (ROE) Growth & History (4BB)
4basebio's return on equity was −92.65% for fiscal 2025.
View full 4basebio company overview4basebio annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −92.65% | +2.63 pp |
| 2024 | 2024-12-31 | −95.28% | +136.01 pp |
| 2023 | 2023-12-31 | −231.29% | — |
4basebio return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, 4basebio's return on equity increased from −231.29% to −92.65%, a change of +138.64 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4basebio source filings ↗Community posts
4basebio expands synthetic-DNA manufacturing for personalised mRNA medicines
4basebio announced an expansion of its DNA offering on 7 September 2026. Manufacturing changes The company has added suite capacity and enhanced process controls and quality systems across its Cambridge high-quality and current-GMP operatio ...